BSE: 0 | NSE: SOTAC | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Sotac Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Sotac Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sotac Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11% | 16.4% | 41.6% | 29.8% | 19.3% | - |
| Value Creation Index ⓘ | -0.2 | 0.2 | 2.0 | 1.1 | 0.4 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | ||||||
| Sales ⓘ | 28.6 | 43.4 | 73.2 | 58 | 67.1 | 67 |
| Sales YoY Gr. | - | 51.9% | 68.4% | -20.7% | 15.8% | - |
| Adj EPS ⓘ | 0.9 | 1.1 | 5.7 | 5.6 | 5.3 | 5.2 |
| YoY Gr. | - | 21.6% | 431.8% | -1.8% | -6.1% | - |
| BVPS (₹) ⓘ | 4.2 | 5.2 | 8.8 | 14.3 | 43.7 | 44.8 |
| Adj Net Profit ⓘ | 0.7 | 0.9 | 4.6 | 4.5 | 5.8 | 6 |
| Cash Flow from Ops. ⓘ | -0.3 | 2.4 | 3.6 | 8.5 | -19.8 | - |
| Debt/CF from Ops. ⓘ | -28.6 | 2.8 | 2.1 | 1.3 | -0.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 15.6% | 15.8% | ||||
| Adj EPS ⓘ | NA | NA | 69.9% | -6.1% | ||||
| BVPSⓘ | NA | NA | 102.8% | 205.3% | ||||
| Share Price | - | - | - | -4.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 20.9 | 22.7 | 80.9 | 32.1 | 16.7 | 11.8 |
| Op. Profit Mgn % ⓘ | 7.2 | 6.5 | 11 | 14.2 | 15.2 | 13.2 |
| Net Profit Mgn % ⓘ | 2.5 | 2 | 6.3 | 7.8 | 8.6 | 8.6 |
| Debt to Equity ⓘ | 2.1 | 1.6 | 1 | 0.9 | 0.2 | - |
| Working Cap Days ⓘ | 0 | 108 | 101 | 171 | 199 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -5 | -15 | -8 | 28 | 0 |
Sales growth is growing at healthy rate in last 3 years 15.60%
Net Profit is growing at healthy rate in last 3 years 69.93%
Debt to equity has declined versus last 3 years average to 0.23
Return on Equity has declined versus last 3 years average to 11.80%
Sales growth is not so good in last 4 quarters at 5.05%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 5.2 | 3.9 |
| TTM Sales (₹ Cr.) | 67.1 | 104 |
| BVPS (₹.) ⓘ | 44.8 | 42.2 |
| Reserves (₹ Cr.) ⓘ | 38 | 36 |
| P/BV ⓘ | 2.44 | 2.60 |
| PE ⓘ | 21.05 | 28.26 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 121 |
| Equity (₹ Cr.) | 11.1 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Sales | 29 | 43 | 73 | 58 | 67 |
| Operating Expenses ⓘ | 27 | 41 | 67 | 50 | 57 |
| Manufacturing Costs | 2 | 2 | 5 | 5 | 0 |
| Material Costs | 21 | 34 | 56 | 40 | 45 |
| Employee Cost | 1 | 2 | 2 | 2 | 3 |
| Other Costs ⓘ | 2 | 2 | 4 | 3 | 9 |
| Operating Profit ⓘ | 2 | 3 | 6 | 8 | 10 |
| Operating Profit Margin (%) | 7.2% | 6.5% | 8.5% | 14.2% | 15.2% |
| Other Income ⓘ | 0 | 0 | 0 | 0 | 1 |
| Interest ⓘ | 0 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 1 | 1 | 1 | 2 | 3 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 1 | 5 | 6 | 8 |
| Tax ⓘ | 0 | 0 | 1 | 1 | 2 |
| Profit After Tax | 1 | 1 | 3 | 4 | 6 |
| PAT Margin (%) | 2.5% | 2.0% | 4.5% | 7.8% | 8.6% |
| Adjusted EPS (₹) | 0.9 | 1.1 | 4.1 | 5.6 | 5.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 14% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 3 | 4 | 7 | 12 | 48 | |||||
| Share Capital ⓘ | 2 | 2 | 2 | 8 | 11 | |||||
| Reserves ⓘ | 1 | 2 | 5 | 3 | 37 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | |||||
| Debt | 7 | 6 | 6 | 9 | 11 | |||||
| Long Term Debt | 3 | 3 | 1 | 7 | 4 | |||||
| Short Term Debt | 4 | 4 | 5 | 2 | 7 | |||||
| Trade Payables | 10 | 10 | 20 | 18 | 15 | |||||
| Others Liabilities ⓘ | 1 | 1 | 3 | 16 | 2 | |||||
| Total Liabilities ⓘ | 21 | 22 | 36 | 55 | 76 | |||||
Fixed Assets | ||||||||||
| Gross Block | 9 | 10 | 11 | 18 | 18 | |||||
| Accumulated Depreciation | 3 | 4 | 2 | 4 | 0 | |||||
| Net Fixed Assetsⓘ | 6 | 6 | 9 | 14 | 18 | |||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | |||||
| Investmentsⓘ | 2 | 2 | 0 | 4 | 11 | |||||
| Inventories | 2 | 4 | 5 | 10 | 11 | |||||
| Trade Receivables | 8 | 6 | 13 | 11 | 22 | |||||
| Cash Equivalents | 0 | 0 | 0 | 10 | 1 | |||||
| Others Assetsⓘ | 2 | 3 | 10 | 6 | 13 | |||||
| Total Assets ⓘ | 21 | 22 | 36 | 55 | 76 | |||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0 | 2 | 4 | 9 | -20 |
| PBT ⓘ | 1 | 1 | 5 | 6 | 8 |
| Adjustment ⓘ | 2 | 2 | 3 | 2 | 0 |
| Changes in Working Capital ⓘ | -2 | -0 | -3 | 2 | -26 |
| Tax Paid ⓘ | 0 | 0 | -1 | -2 | -2 |
| Cash Flow From Investing Activity ⓘ | -2 | -1 | -3 | -11 | -13 |
| Capex | 0 | -1 | -4 | -7 | -6 |
| Net Investments | -2 | 0 | 0 | -4 | -7 |
| Others ⓘ | 0 | 0 | 0 | 0 | 1 |
| Cash Flow From Financing Activityⓘ | 2 | -1 | 0 | 12 | 23 |
| Net Proceeds from Shares ⓘ | 1 | 0 | 0 | 9 | 33 |
| Net Proceeds from Borrowing ⓘ | -4 | 0 | -6 | 6 | -2 |
| Interest Paid ⓘ | 0 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 5 | 0 | 6 | -2 | -7 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 10 | -9 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 20.93 | 22.71 | 58.23 | 48.29 | 19.23 | |||||
| ROCE (%) | 10.98 | 16.43 | 41.56 | 29.76 | 19.25 | |||||
| Asset Turnover Ratio | 1.35 | 2.02 | 2.51 | 1.27 | 1.03 | |||||
| PAT to CFO Conversion(x) | 0 | 2 | 1.33 | 2.25 | -3.33 | Working Capital Days | ||||
| Receivable Days | 104 | 59 | 46 | 76 | 91 | |||||
| Inventory Days | 30 | 26 | 23 | 47 | 56 | |||||
| Payable Days | 170 | 108 | 98 | 173 | 133 | |||||
The company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 (Partnership Act) in the name and style of Sotac Pharmaceuticals, pursuant to a deed of partnership dated December 10, 2014. Thereafter Sotac Pharmaceuticals was converted from Partnership Firm to a Private Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of Sotac Pharmaceuticals Private Limited and received a certificate of incorporation dated December 18, 2015 from the Assistant Registrar of Companies, Gujarat. Later on the company was converted into a Public Limited Company pursuant to shareholders resolution passed at Extra-ordinary General Meeting of the Company held on November 12, 2022 and the name of the Company was changed to Sotac Pharmaceuticals Limited. A fresh Certificate of Incorporation consequent upon Conversion from Private Limited Company to Public Limited Company dated November 22, 2022 was issued by the Registrar of Companies, Ahmedabad.
Sotac Pharmaceuticals is in business of manufacturing of pharmaceutical products for different marketers on loan license or contract manufacturing basis. Its business is majorly on principle to principle basis with different marketers. The company caters to corporate clients on loan licence and/or contract manufacturing basis. The company has commenced manufacturing facility in year 2017, hence, the company has experience of more than 5 years in the current line of business of the company. In year 2017, the company’s manufacturing facility was installed with capacity to manufacture 90 crore tables / year, 14 crore Capsules / year.
Business area of the company
The company specializes in the production of high-quality pharmaceutical products on a loan license or contract manufacturing basis. It has a diverse product portfolio that includes a wide range of pharmaceuticals, nutraceuticals, and food products.
Key Events/Milestone/ Achievement
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
